Ocugen (NASDAQ:OCGN) Sees Strong Trading Volume – Should You Buy?

Ocugen, Inc. (NASDAQ:OCGN) saw unusually-strong trading volume on Tuesday . Approximately 6,755,595 shares were traded during trading, a decline of 13% from the previous session’s volume of 7,768,395 shares.The stock last traded at $1.8150 and had previously closed at $2.10.

More Ocugen News

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: Phase 2 topline shows efficacy and safety: The medium (optimal) dose produced a statistically significant 31% reduction in GA lesion growth at 12 months versus control, with no OCU410‑related serious adverse events reported — a clear positive clinical readout. GlobeNewswire Release
• Positive Sentiment: Commercial potential and next steps: Management highlighted a potential ~2x benefit vs. existing therapies, plans a Phase 3 registrational trial in Q3 2026 (up to ~300 subjects, adaptive design), and positions OCU410 as a one‑time gene therapy — factors that support sizable long‑term upside if confirmed. QuiverQuant Summary
• Positive Sentiment: Index inclusion raises visibility: Ocugen was added to the S&P Biotechnology Select Industry Index, which can increase passive/fund demand and broader investor attention. Yahoo Finance
• Neutral Sentiment: Investor presentation/webcast: Ocugen hosted a webcast with KOLs and management to discuss the full Phase 2 dataset, providing more detail for analysts and investors to digest. Webcast Notice
• Neutral Sentiment: Market positioning and recent run-up: Recent strong gains have already repriced expectations for OCU410; pieces discussing valuation and whether the rally is extended may temper near‑term buying. Yahoo: Is It Too Late?
• Negative Sentiment: Immediate sell‑side reaction and share decline: Despite positive topline data, the stock fell as some investors took profits and others remain cautious until larger, confirmatory Phase 3 data are available — headlines flagged the drop. Seeking Alpha
• Negative Sentiment: Clinical and execution risks remain: The Phase 2 cohort was small (51 patients), results are topline/interim, and management’s forward statements note standard regulatory/clinical uncertainties — Phase 3 success is not guaranteed. MSN Coverage
• Negative Sentiment: Fundamentals and volatility: Ocugen remains a loss‑making, highly volatile biotech (historical swings, thin financials), so any setback or need for capital could pressure the stock further. (Background trading data provided by the user.)

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on OCGN shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ocugen in a research note on Thursday, January 22nd. Oppenheimer started coverage on shares of Ocugen in a report on Wednesday, March 11th. They set an “outperform” rating and a $10.00 target price for the company. Wall Street Zen upgraded shares of Ocugen from a “sell” rating to a “hold” rating in a research report on Saturday. Canaccord Genuity Group initiated coverage on shares of Ocugen in a research report on Tuesday, March 17th. They set a “buy” rating and a $12.00 price target on the stock. Finally, Chardan Capital reiterated a “buy” rating and issued a $7.00 price objective on shares of Ocugen in a report on Thursday, March 5th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

Ocugen Price Performance

The firm has a market cap of $611.53 million, a price-to-earnings ratio of -8.11 and a beta of 2.75. The stock’s fifty day moving average price is $1.73 and its 200-day moving average price is $1.52. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 8.04.

Ocugen (NASDAQ:OCGN) last issued its quarterly earnings data on Wednesday, March 4th. The company reported ($0.06) earnings per share for the quarter, hitting the consensus estimate of ($0.06). The company had revenue of ($0.19) million during the quarter, compared to analyst estimates of $0.86 million. Ocugen had a negative return on equity of 2,626.38% and a negative net margin of 1,192.18%. As a group, equities research analysts forecast that Ocugen, Inc. will post -0.2 earnings per share for the current fiscal year.

Institutional Trading of Ocugen

Institutional investors and hedge funds have recently bought and sold shares of the stock. SmartHarvest Portfolios LLC acquired a new position in Ocugen in the fourth quarter valued at about $31,000. BNP Paribas Financial Markets raised its stake in shares of Ocugen by 56.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company’s stock valued at $36,000 after acquiring an additional 13,326 shares during the period. NewEdge Advisors LLC lifted its holdings in shares of Ocugen by 198.0% in the 2nd quarter. NewEdge Advisors LLC now owns 36,814 shares of the company’s stock worth $36,000 after acquiring an additional 24,460 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in shares of Ocugen in the 4th quarter worth approximately $38,000. Finally, Cora Capital Advisors LLC boosted its position in shares of Ocugen by 27.5% during the 4th quarter. Cora Capital Advisors LLC now owns 30,143 shares of the company’s stock worth $41,000 after purchasing an additional 6,500 shares during the period. 10.27% of the stock is currently owned by hedge funds and other institutional investors.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.